368,305 Shares in Xencor, Inc. $XNCR Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 368,305 shares of the biopharmaceutical company’s stock, valued at approximately $7,828,524,000. Xencor accounts for 1.3% of Seven Fleet Capital Management LP’s holdings, making the stock its 17th biggest position. Seven Fleet Capital Management LP owned approximately 0.50% of Xencor at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of XNCR. ProShare Advisors LLC grew its position in shares of Xencor by 6.5% during the 4th quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock valued at $258,000 after acquiring an additional 1,026 shares during the period. Cerity Partners LLC boosted its position in Xencor by 3.8% during the fourth quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock worth $479,000 after purchasing an additional 1,143 shares in the last quarter. State of Tennessee Department of Treasury grew its holdings in Xencor by 6.2% in the second quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 1,784 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Xencor by 3.3% in the second quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company’s stock valued at $550,000 after buying an additional 2,256 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares during the period.

Analysts Set New Price Targets

A number of research firms recently issued reports on XNCR. Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Wedbush upped their price objective on shares of Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. JPMorgan Chase & Co. increased their price objective on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Monday, May 11th. Finally, Cantor Fitzgerald lifted their target price on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xencor has a consensus rating of “Hold” and an average target price of $24.86.

Xencor Trading Down 2.9%

XNCR opened at $28.44 on Thursday. Xencor, Inc. has a twelve month low of $7.80 and a twelve month high of $30.61. The firm has a market capitalization of $2.11 billion, a PE ratio of -13.11 and a beta of 0.85. The firm’s 50-day moving average price is $19.21 and its 200 day moving average price is $14.57.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same quarter in the prior year, the firm earned ($0.41) EPS. Xencor’s quarterly revenue was up 17.4% on a year-over-year basis. As a group, analysts predict that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.